Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor

Cancer Immunol Immunother. 2007 Sep;56(9):1335-44. doi: 10.1007/s00262-007-0281-8. Epub 2007 Feb 1.

Abstract

One immunization with murine polyomavirus (MPyV) VP1 virus-like particles containing a fusion protein between MPyV VP2 and the extra cellular and transmembrane domain of Her2 (Her2(1-683)PyVLPs) efficiently protects BALB/c mice from outgrowth of the Her2 expressing tumor D2F2/E2. To possibly enhance the anti-Her2 immune response and abrogate the induced anti-VLP antibody response, immunization with murine dendritic cells (DCs) loaded with Her2(1-683)PyVLPs was performed. Mice were immunized once or more with 5 or 50 microg Her2(1-683)PyVLPs alone or loaded on DCs, and challenged 14 days after the last immunization with a lethal dose of Her2-positive D2F2/E2 cells. Mice were protected from tumor outgrowth, when immunized only once with 5 or 50 mug Her2(1-683)PyVLPs loaded on DCs, or 50 mug of Her2(1-683)PyVLPs alone, whereas immunization once or more with 5 mug of Her2(1-683)PyVLPs alone only protected half of the mice. Immunization with recombinant Her2 protein alone, or loaded on DCs, did not induce tumor immunity. Using both immunization strategies, Her2-specific T cell immunity was demonstrated, while Her2-specific antibodies were not detected. Loading VLPs on DCs reduced anti-VLP antibodies sixfold, but did not influence the efficiency of subsequent immunizations. Notably, DC maturation by Her2(1-683)PyVLPs in vitro was not demonstrated although the IL-12 production was significantly increased. In conclusion, loading of VLPs on DCs can enhance specific VLP immunization considerably.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Capsid Proteins / genetics
  • Capsid Proteins / immunology
  • Capsid Proteins / therapeutic use*
  • Cell Line
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Dendritic Cells / transplantation
  • Female
  • Humans
  • Interleukin-12 / metabolism
  • Mammary Neoplasms, Experimental / immunology
  • Mammary Neoplasms, Experimental / therapy*
  • Mice
  • Mice, Inbred BALB C
  • Peptide Fragments / immunology
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / immunology*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use*
  • T-Lymphocytes / immunology

Substances

  • Cancer Vaccines
  • Capsid Proteins
  • Peptide Fragments
  • Recombinant Fusion Proteins
  • VP1 protein, polyomavirus
  • VP2 protein, Polyomavirus
  • Interleukin-12
  • Receptor, ErbB-2